Vedanta Biosciences, Inc.

Overview

Vedanta Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, founded in 2010. The company focuses on developing oral therapies that utilize rationally defined consortia of human commensal bacteria to treat immune-mediated and gastrointestinal diseases. Founded by PureTech Health and a team of experts in immunology and microbiome research, Vedanta aims to advance treatment options by creating standardized, live bacterial medicines derived from the human microbiome.

The therapeutic pipeline features several candidates, including VE303, targeting Clostridioides difficile infection and advancing toward Phase 3 clinical trials. Other key candidates are VE707, in preclinical development for multidrug-resistant organism infections, and VE202, investigated for ulcerative colitis. Vedanta also offers research and development services, supported by proprietary manufacturing capabilities for scalable production of therapies, driving innovations for patients with immune-mediated and gastrointestinal conditions.

Basic Information

Contact Details

• Phone: +1 857-706-1427
• Website: vedantabio.com
• LinkedIn: linkedin.com/company/vedanta-biosciences-inc-

Key Focus Areas & Initiatives

• Human microbiome & mucosal immunology
• Biotechnology research
• Microbiome clinical trials
• Defined bacterial consortia
• Oral therapies
• Microbiome safety
• Gastrointestinal diseases
• Microbiome therapeutics
• Inflammatory bowel disease
• Microbiome immune modulation
• Gut dysbiosis
• Microbiome drug development
• Microbiome research
• Live biotherapeutic products
• Health care innovation
• Pharmaceutical manufacturing
• Patient care
• Manufacturing & supply chain management
• Hospital & health care
• Mechanical or industrial engineering

Technologies Used

• Apache
• Google Analytics
• Google Font API
• Google Tag Manager
• Microsoft Office 365
• Mobile Friendly
• Outlook
• Remote
• Wistia
• WordPress.org